Literature DB >> 34189590

[Systemic treatment of moderate/severe hidradenitis suppurativa].

A Pinter1, U Mrowietz2, T Volz3.   

Abstract

Systemic treatment together with radical surgical excision is the most important treatment option for all severity grades of hidradenitis suppurativa. Tetracycline in mild-to-moderate forms and clindamycin in combination with rifampicin in moderate-to-severe forms are guideline-compliant first-line therapy with a good clinical response. Other antibiotics such as ertepenem or multiple combinations are recommended as last-line therapy due to a lack of data. Success rate with dapsone and retinoids, on the other hand, are insufficient-only acitretin can be recommended on the basis of the available studies, but with limited success. With the TNF-alpha blocker adalimumab, an effective and safe long-term therapy is available-further biologics are in clinical trials and could significantly expand the treatment portfolio in the future.
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Antibiotics; Biological products; Long-term treatment; Retinoids; Treatment outcomes

Year:  2021        PMID: 34189590     DOI: 10.1007/s00105-021-04844-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  6 in total

1.  The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study.

Authors:  Kelsey R van Straalen; Thrasyvoulos Tzellos; Phillipe Guillem; Farida Benhadou; Carlos Cuenca-Barrales; Mathilde Daxhelet; Mathieu Daoud; Ourania Efthymiou; Evangelos J Giamarellos-Bourboulis; Gregor B E Jemec; Alexandros C Katoulis; Anke Koenig; Elizabeth Lazaridou; Angelo V Marzano; Łucas Matusiak; Alejandro Molina-Leyva; Chiara Moltrasio; Andreas Pinter; Concetta Potenza; Jorge Romaní; Ditte M Saunte; Nevena Skroza; Dimitra Stergianou; Jacek Szepietowski; Anastasia Trigoni; Eva Vilarrasa; Hessel H van der Zee
Journal:  J Am Acad Dermatol       Date:  2021-01-20       Impact factor: 11.527

2.  Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa.

Authors:  Matteo Megna; Angelo Ruggiero; Adriana Di Guida; Angela Patrì; Gabriella Fabbrocini; Claudio Marasca
Journal:  Dermatol Ther       Date:  2020-06-29       Impact factor: 2.851

3.  Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age.

Authors:  R Verdolini; F Simonacci; S Menon; P Pavlou; B Mannello
Journal:  G Ital Dermatol Venereol       Date:  2014-06-13       Impact factor: 2.011

4.  Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study.

Authors:  Astrid-Helene Ravn Jørgensen; Yiqiu Yao; Simon Francis Thomsen; Hans Christian Ring
Journal:  Int J Dermatol       Date:  2021-03-04       Impact factor: 2.736

5.  Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa.

Authors:  Y Cao; F Hong; D M Conlon; L Sidur; K M Smith; Y Fang; C A Cuff; Z Kaymakcalan; M C Ruzek
Journal:  Br J Dermatol       Date:  2021-04-02       Impact factor: 9.302

6.  Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.

Authors:  Viola Harde; Ulrich Mrowietz
Journal:  J Dtsch Dermatol Ges       Date:  2009-02       Impact factor: 5.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.